menu

QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

distribution
Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
Filtered by 'Market Access' ×
Sarah Rickwood
What it takes to thrive in an increasingly specialized marketplace.
Read More
Mark Mozeson
How will the US pharma market evolve during the period 2017-2021?
Read More
John Doyle
Expectations for RWE are shaping the value conversation in healthcare. At this year’s ISPOR, we will explore what this trend means for pharma and how they can generate the most benefit from these studies.
Read More
Anke van Engen
The adaptive pathway offers a number of real benefits, but sponsors must be prepared to face challenges in demonstrating the safety and effectiveness of treatments brought to market through this approach.
Read More
Anke van Engen
How the Japanese government’s efforts to rein-in pharma spending will effect drug prices across the country.
Read More
John Doyle
John Doyle
The potential benefits of regenerative medicine are huge, but the increased complexity of developing and applying these therapies presents market access challenges.
Read More
Jeremy Broadis
Obtaining regional and local market access in the age of health technology assessments.
Read More
Anke van Engen
How this relatively new US-based HTA framework could change the conversation about value and affordability.
Read More
Anke van Engen
Developers pursing accelerated pathways should work with payers to understand what evidence needs to be obtained to increase the chance of a positive recommendation.
Read More